In the first video of a series with Marina Konopleva, MD, PhD, recorded during the 2022 SOHO Annual Meeting, she discusses venetoclax resistance in acute myeloid leukemia (AML).
How to Overcome Resistance to Venetoclax According to Marina Konopleva, MD, PhD
By Leah Sherwood - Last Updated: November 14, 2022Post Tags:SOHO 2022
Related Posts
A UC researcher secures $500K+ in grants to explore RAS inhibitors as potential treatments for acute myeloid leukemia.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Naval Daver, MD reviews new targeted therapies transforming AML treatment in both young and older patient groups.
The name change will take effect on August 28, ahead of Blood Cancer Awareness Month in September.
A post-hoc analysis of long-term results in the AGILE trial adds to promising initial efficacy and safety results.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.